封面
市场调查报告书
商品编码
1316476

癌症免疫疗法药物研发发现外包市场:按癌症类型、药物类型、服务类型划分 - 全球预测 2023-2030

Cancer Immunotherapy Drug Discovery Outsourcing Market by Cancer Type, Drug Type, Service Type - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球癌症免疫疗法药物研发外包市场将达到16.0191亿美元,复合年增长率为15.52%,大幅成长,2030年将达到惊人的44.1696亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球癌症免疫疗法药物研发外包市场至关重要。透过检验业务策略和产品满意度的关键指标,我们对供应商进行全面评估,使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限,并取得了不同程度的成功:前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对整体收入、基本客群和其他关键指标的贡献,可以帮助公司更好地了解自家公司在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解:

1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。

2. 市场开发:提供有关利润丰厚的新兴市场的详细资讯,并分析其在成熟市场的渗透率。

3. 市场多元化:提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势:全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题:

1.癌症免疫治疗药物研发外包的全球市场规模和预测是多少?

2.在预测期内,COVID-19 对全球癌症免疫疗法药物研发发现外包市场的阻碍因素和影响是什么?

3. 在预测期内,全球癌症免疫治疗药物研发外包市场需要投资哪些产品/细分市场/用途/领域?

4.全球癌症免疫治疗药物药物研发外包市场的竞争策略为何?

5.全球癌症免疫治疗药物药物研发外包市场的技术趋势和法律规范是什么?

6.全球癌症免疫治疗药物药物研发外包市场主要供应商的市占率是多少?

7. 哪些型态和策略性措施被认为适合进入全球癌症免疫疗法药物研发外包市场?

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症盛行率上升
      • 提高医生和病人对免疫治疗的认识
      • 增加对开发癌症治疗方法的投资
    • 抑制因素
      • 药物开发和治疗费用昂贵
    • 机会
      • 增加临床试验以开发有效的癌症免疫疗法
      • 扩大与製药公司的 CDMO 合作
    • 任务
      • 严格的政府法规和指导方针
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章癌症免疫治疗药物研发外包市场:按癌症类型

  • 介绍
  • 胸部
  • 大肠直肠
  • 头部和颈部
  • 黑色素瘤
  • 子房
  • 胰臟
  • 摄护腺

第7章癌症免疫治疗药物研发外包市场:按药物类型

  • 介绍
  • 免疫调节剂
  • 单株抗体
  • 溶瘤病毒疗法和癌症疫苗

第8章癌症免疫治疗药物研发外包市场:依服务类型

  • 介绍
  • 基于细胞的检测
  • 铅筛选与表征
  • 目标识别与检验

第9章北美和南美癌症免疫疗法药物研发发现外包市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太癌症免疫治疗药物研发发现外包市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲癌症免疫疗法药物研发外包市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析:主要企业
  • 竞争情境分析:主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-205091A88728

The Global Cancer Immunotherapy Drug Discovery Outsourcing Market is forecasted to grow significantly, with a projected USD 1,601.91 million in 2023 at a CAGR of 15.52% and expected to reach a staggering USD 4,416.96 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Immunotherapy Drug Discovery Outsourcing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Cancer Type, market is studied across Breast, Colorectal, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, and Prostate. The Lung is projected to witness significant market share during forecast period.

Based on Drug Type, market is studied across Immunomodulators, Monoclonal Antibodies, and Oncolytic Viral Therapies & Cancer Vaccines. The Immunomodulators is projected to witness significant market share during forecast period.

Based on Service Type, market is studied across Cell-based Assays, Lead Screening & Characterization, and Target Identification & Validation. The Lead Screening & Characterization is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Drug Discovery Outsourcing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

6. What is the market share of the leading vendors in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type, 2022 vs 2030
  • 4.3. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type, 2022 vs 2030
  • 4.4. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type, 2022 vs 2030
  • 4.5. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Increasing awareness regarding immunotherapy among physicians and patients
      • 5.1.1.3. Increasing investments for the development of cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in clinical trials for development of efficient cancer immunotherapy
      • 5.1.3.2. Increasing CDMO collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and guidelines
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast
  • 6.3. Colorectal
  • 6.4. Head and Neck
  • 6.5. Lung
  • 6.6. Melanoma
  • 6.7. Ovarian
  • 6.8. Pancreatic
  • 6.9. Prostate

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Immunomodulators
  • 7.3. Monoclonal Antibodies
  • 7.4. Oncolytic Viral Therapies & Cancer Vaccines

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Cell-based Assays
  • 8.3. Lead Screening & Characterization
  • 8.4. Target Identification & Validation

9. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
  • FIGURE 5. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
  • FIGURE 9. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OVARIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PANCREATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRAL THERAPIES & CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD SCREENING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 149. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 150. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET LICENSE & PRICING